戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              HBOC-201 achieved tissues oxygen saturation equivalent t
2                                              HBOC-201 consists of polymerized bovine hemoglobin and h
3                                              HBOC-201 is an excellent alternative to blood as an oxyg
4                                              HBOC-related breast cancers accumulated significantly mo
5                                              HBOCs have several advantages over human blood, includin
6 missense variant, L1420F, was observed in 13 HBOC families (4.8%) but was not observed in any of the
7 and brain oxygen for the first 8 hrs; and 2) HBOC-201 could be an effective salvage therapy after sev
8 hase," pigs were resuscitated with HBOC-201 (HBOC) or Hextend (HEX) or were nonresuscitated (NON).
9                                       In 270 HBOC families previously screened for BRCA1 and BRCA2 mu
10 f potential significance were observed in 65 HBOC families, but not in healthy controls.
11 ally investigated how low- and high-affinity HBOCs would perform in normoxic and hypoxic tumors.
12 ta are absent in most of these syndromes, an HBOC diagnosis may be missed unless a careful family his
13 els were similarly reduced by both blood and HBOC-201.
14 idered as BRCA1-like biomarkers for TNBC and HBOC syndrome.
15 at the oxygen (O(2)) status of the tumor and HBOC O(2) affinity may play a role in increased O(2) del
16 tly reported pathogenic variant in Brazilian HBOC patients, was not observed.
17 sion of TP53 in routine testing of Brazilian HBOC patients.
18 ate the pulmonary vasoconstriction caused by HBOC.
19 RR, 2.30; 95% CI, 2.22 to 2.40), followed by HBOC and LS (both with 1 < RR < 2 and statistically sign
20 ls for hereditary breast and ovarian cancer (HBOC) due to its BRCA1-related molecular function in the
21 for hereditary breast and/or ovarian cancer (HBOC) is rapidly evolving owing to the recent introducti
22 uch as hereditary breast and ovarian cancer (HBOC), consider genetic testing, especially in the setti
23 elated hereditary breast and ovarian cancer (HBOC), Lynch syndrome (LS) and familial hypercholesterol
24 sk for hereditary breast and ovarian cancer (HBOC).
25 isk of hereditary breast and ovarian cancer (HBOC).
26 ome of hereditary breast and ovarian cancer (HBOC).
27  both [hereditary breast and ovarian cancer (HBOC)].
28          DBBF-Hb, a Hb-based oxygen carrier (HBOC) for which toxic side effects have been well docume
29 n acellular hemoglobin-based oxygen carrier (HBOC) Hemopure in a human model of NMP-L.
30 a potential hemoglobin-based oxygen carrier (HBOC) in in vivo animal studies.
31  cell-free, hemoglobin-based oxygen carrier (HBOC) is systemic vasoconstriction.
32 t to assess hemoglobin-based oxygen carrier (HBOC-201) in oxygen delivery to the kidney for renal pro
33 AAP) with a hemoglobin-based oxygen carrier (HBOC-201) offers a potentially effective therapy.
34            Hemoglobin-based oxygen carriers (HBOC) of several types scavenge nitric oxide from the va
35 nthetic hemoglobin (Hb)-based O(2) carriers (HBOCs) represent a promising approach to mitigate hypoxi
36 itated by hemoglobin (Hb)-based O2 carriers (HBOCs) is a promising strategy to increase the effective
37  including hemoglobin-based oxygen carriers (HBOCs) and perfluorocarbons.
38 rty years, hemoglobin-based oxygen carriers (HBOCs) have been under development as a red blood cell s
39 tration of hemoglobin-based oxygen carriers (HBOCs) into the systemic circulation is a potential stra
40 rtain hemoglobin (Hb)-based oxygen carriers (HBOCs) may alter Hb structure and function, as amino aci
41            Hemoglobin-based oxygen carriers (HBOCs) of bovine hemoglobin (Hb) or human Hb origin were
42  blood or Haemoglobin-based oxygen carriers (HBOCs).
43  acellular hemoglobin-based oxygen carriers (HBOCs).
44 iable hemoglobin (Hb)-based oxygen carriers (HBOCs).
45                                     Combined HBOC and sildenafil infusion resulted in stable systemic
46 port the continued investigation of combined HBOC and PDE5 inhibitor treatment in circumstances in wh
47 treatment can be largely overcome by combing HBOC treatment with a PDE5 inhibitor (sildenafil).
48 e hemoglobin-based oxygen carrying compound (HBOC-201) was administered to enhance the patient's oxyg
49 , hemoglobin-based oxygen carrying compound [HBOC]-201, Biopure).
50 ointed in two unrelated French-Canadian (FC) HBOC patients.
51 ividuals who were appropriate candidates for HBOC evaluation and who lacked BRCA1/2 mutations.
52 her MRE11A is a true predisposition gene for HBOC is still questionable.
53 y be a new genetic marker of cancer risk for HBOC families without other known genetic abnormalities.
54 mogram frequency based on their low risk for HBOC, and to examine if cognitive and emotional factors
55 had no evidence of prior genetic testing for HBOC in their EHR.
56 entative cohort, multigene panel testing for HBOC risk assessment yielded findings likely to change c
57 ikely pathogenic (P/LP) genetic variants for HBOC, LS and FH.
58 apable of distinguishing plasma samples from HBOC patients as BRCA1-mutated and BRCA1 non-mutated, su
59 , and managing patients at high risk for HBC/HBOC.
60 lutaraldehyde-polymerized bovine hemoglobin (HBOC) with a PDE5 inhibitor would counter the negative h
61 lutaraldehyde-polymerized bovine hemoglobin (HBOC), sildenafil (PDE5 inhibitor), and lactated Ringer'
62 lutaraldehyde-polymerized bovine hemoglobin (HBOC-201, 1.44 g/kg).
63               In comparison with hetastarch, HBOC-201 resuscitation of swine with HS increased surviv
64                              Histologically, HBOC-201 and blood-perfused kidneys had vastly reduced a
65 was evaluated for FH of hereditary PC (HPC), HBOC, and Lynch syndrome (LS) and for his own PC status.
66 ar size tetrameric species (i.e., 64 kDa) in HBOC solutions.
67 c enzymes were generally similar or lower in HBOC than HEX pigs, but creatine kinase-MB (but not crea
68 ack of clinical utility of MRE11A testing in HBOC, at least in the White/Caucasian populations.
69         Together, our data indicate that, in HBOC-related breast cancers, the accumulation of genomic
70  that the KRAS-variant was present in 61% of HBOC patients without BRCA1 or BRCA2 mutations, previous
71  had no significant effect on the actions of HBOC-201.
72                                 The basis of HBOC toxicity is poorly understood, however, several mec
73                         1) A single bolus of HBOC-201 at initial resuscitation rapidly restored cereb
74 ter the negative hemodynamic consequences of HBOC therapy alone, resulting in improved hemodynamics a
75               These negative consequences of HBOC treatment can be largely overcome by combing HBOC t
76                               The effects of HBOC-201-resuscitation in HS should be corroborated in c
77                          Two formulations of HBOC-201 (average MW = 250 kDa) were tested: one with <3
78 inistered before the intravenous infusion of HBOC can prevent systemic vasoconstriction without causi
79 ypertension caused by subsequent infusion of HBOC-201.
80 s were performed regarding the prevalence of HBOC pathogenic variants in this context.
81  was to determine the metabolic signature of HBOC syndrome and TNBC patients and to evaluate the pote
82                             Only a subset of HBOC family members are likely to request BRCA1 testing
83 P53 genes in Brazilian patients suspected of HBOC and referred to public healthcare service.
84 toxicity have prevented clinical approval of HBOCs.
85  useful in the detection and confirmation of HBOCs in test samples.
86 entification, detection, and confirmation of HBOCs of bovine Hb or human Hb origin.
87 entification, detection, and confirmation of HBOCs.
88 ation, quantification, and distinguishing of HBOCs from native hemoglobin in test samples is needed.
89 ates evaluating the oxygenation potential of HBOCs within the tumor microenvironment.
90 r autoxidation in evaluating the toxicity of HBOCs.
91 ize (i.e., 64 kDa) has a direct influence on HBOC-mediated vasoactivity and that other protective str
92 of either normal saline (control, n = 14) or HBOC-201 (n = 14) was administered.
93 istration of murine tetrameric hemoglobin or HBOC-201 and did not result in conversion of plasma hemo
94 on of either murine tetrameric hemoglobin or HBOC-201 induced prolonged systemic vasoconstriction in
95 LR) solution (n = 6) or SAAP with oxygenated HBOC-201 (n = 6) at a rate of 10 mL x kg(-1) x min(-1) u
96                         SAAP with oxygenated HBOC-201 rapidly restored viable cardiovascular function
97 ional phase III trial of the Biopure product HBOC-201 (Hemopure) has been completed in orthopedic sur
98 K makes this protein an especially promising HBOC prototype.
99 at needs to be solved to develop recombinant HBOCs as safe transfusion agents.
100               Furthermore, upon reperfusion, HBOC-201 treated kidneys had similar renal blood flow an
101 " engineering strategy to construct a robust HBOC by integrating hierarchically porous UiO-66 NPs (HP
102 ne-hour survival was five of six in the SAAP-HBOC group and none of six in the SAAP-LR group (p <.05,
103                                  In the SAAP-HBOC group, return of spontaneous circulation with a sus
104 l stability with the aim of designing stable HBOCs.
105 reditary breast and ovarian cancer syndrome (HBOC) as well as their family members.
106 reditary breast and ovarian cancer syndrome (HBOC) is partly due to the presence of mutations in the
107 reditary breast and ovarian cancer syndrome (HBOC), and meeting family history criteria for BRCA1/2 g
108 h hereditary breast/ovarian cancer syndrome (HBOC).
109 n hereditary breast/ovarian cancer syndrome (HBOC).
110              These findings demonstrate that HBOC can cause systemic vasoconstriction by scavenging N
111                We tested the hypothesis that HBOC-201 would improve cerebrovascular resuscitation in
112                                          The HBOC used in this study resulted in pulmonary and system
113                                          The HBOC-perfused livers extracted more oxygen than those pe
114           In this study, we examined how the HBOC, polymerized human hemoglobin (PolyhHb), in the rel
115 t additional property is the capacity of the HBOC either to generate nitric oxide (NO) or to preserve
116 otion- and cognition-based processing of the HBOC screen result will be important for strategizing co
117 ional and vasoactive characteristics of this HBOC.
118 tabolomic analysis of plasma samples from TN HBOC patients taking into account their BRCA1 genotype.
119       However, the addition of sildenafil to HBOC did not fully ameliorate the pulmonary vasoconstric
120 nhibitor treatment in circumstances in which HBOC therapy is being considered.
121                            In contrast, with HBOC-201 at 30 mins (n = 14), systolic arterial pressure
122 al biliary changes occurred exclusively with HBOC.
123 pillary injury occurred more frequently with HBOC, but consistent patterns for urine output, blood ur
124 se-MB/creatine kinase ratio) was higher with HBOC in moderate controlled HS.
125 r with HBOC and HEX, but Po2 was higher with HBOC in severe uncontrolled HS.
126       Survival was significantly higher with HBOC than HEX only with severe uncontrolled HS (p = .002
127 aline phosphatase were generally higher with HBOC than HEX.
128 an RM3 pump at 22 degrees C for 4 hours with HBOC-201 and blood.
129                                However, with HBOC-201, pressor and fluid requirements were reduced by
130 ed high-risk human livers were perfused with HBOC-based perfusion fluid and matched to 5 RBC-perfused
131 hospital phase," pigs were resuscitated with HBOC-201 (HBOC) or Hextend (HEX) or were nonresuscitated
132 ovascular and metabolic effects of SAAP with HBOC-201 in an exsanguination model of cardiac arrest.
133 nterstitial pulmonary edema was similar with HBOC and HEX, but Po2 was higher with HBOC in severe unc
134     To deter athletes from blood doping with HBOCs such as Hemopure and Oxyglobin (OXY), a method for

 
Page Top